Robin Theresa Lunsford Sr, MS, BCBA in Bremerton, WA - Behavior Analyst

Robin Theresa Lunsford Sr, MS, BCBA is a Behavior Analyst based in Bremerton, Washington. Robin Theresa Lunsford Sr is licensed to practice in * (Not Available) (license number 1-04-1817) and her current practice location is 7658 Trica Ave Ne, Bremerton, Washington. She can be reached at her office (for appointments etc.) via phone at (360) 801-0003.

NPI number for Robin Theresa Lunsford Sr is 1568504785 and her current mailing address is 7658 Trica Ave Ne, Bremerton, Washington. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1568504785.

Contact Information

	Robin Theresa Lunsford Sr, MS, BCBA
	7658 Trica Ave Ne, Bremerton, WA 98311-4010
	(360) 801-0003
	(360) 801-0003

Healthcare Provider's Profile

Full Name	Robin Theresa Lunsford Sr
Gender	Female
Speciality	Behavior Analyst
Location	7658 Trica Ave Ne, Bremerton, Washington
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1568504785
Provider Enumeration Date: 02/13/2007
Last Update Date: 06/19/2015

Medical Identifiers

Medical identifiers for Robin Theresa Lunsford Sr such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1568504785	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
103TM1800X	Psychologist - Intellectual & Developmental Disabilities	(* (Not Available))	Secondary
103K00000X	Behavior Analyst	1-04-1817 (* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Robin Theresa Lunsford Sr is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Robin Theresa Lunsford Sr, MS, BCBA 7658 Trica Ave Ne, Bremerton, WA 98311-4010 Ph: (360) 801-0003	Robin Theresa Lunsford Sr, MS, BCBA 7658 Trica Ave Ne, Bremerton, WA 98311-4010 Ph: (360) 801-0003

News Archive

Researchers suggest potentially valuable role for minocycline plus N-acetylcysteine to treat TBI

Traumatic brain injury is a serious public health problem in the United States. Recent data show that approximately 1.7 million people sustain a traumatic brain injury annually. While the majority of TBIs are concussions or other mild forms, traumatic brain injuries contribute to a substantial number of deaths and cases of permanent disability.

Fibrocell Science submits response to FDA CR letter for azficel-T BLA

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted its complete response to the Complete Response (CR) letter issued by the U.S. Food & Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) for azficel-T, proposed brand name laViv®, for the treatment of moderate to severe nasolabial folds and wrinkles.

Global Health Council names Jeffrey Sturchio as next leader

Jeffrey L. Sturchio, a longtime leader at Merck & Co. whose quiet diplomacy helped build programs treating more than 100,000 AIDS patients in Botswana as well as protecting millions of Africans from river blindness, has been named President and CEO of the Global Health Council, the Council's board of directors announced today.

Scientists identify molecular mechanism that contributes to pancreatic cancer

New research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) and Baylor College of Medicine could aid efforts to diagnose and treat one of the most lethal and hard-to-treat types of cancer.

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.

Robin Theresa Lunsford Sr, MS, BCBA - in Bremerton, WA